Please use this identifier to cite or link to this item:
Title: Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis.
Authors: Mendonça, Ludmila Zanandreis de
Resende, Lucilene Aparecida
Lanna, Mariana Ferreira
Soares, Rodrigo Dian de Oliveira Aguiar
Roatt, Bruno Mendes
Castro, Renata Alves de Oliveira e
Batista, Maurício Azevedo
Lemos, Denise da Silveira
Estanislau, Juliana de Assis Silva Gomes
Fujiwara, Ricardo Toshio
Rezende, Simone Aparecida
Martins Filho, Olindo Assis
Oliveira, Rodrigo Corrêa de
Dutra, Walderez Ornelas
Reis, Alexandre Barbosa
Giunchetti, Rodolfo Cordeiro
Keywords: Immunogenicity
Issue Date: 2016
Citation: MENDONÇA, L. Z. et al. Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis. Parasites & Vectors, v. 9, p. 472, 2016. Disponível em: <>. Acesso em: 29 ago. 2017.
Abstract: Background: In past years, many researchers have sought canine visceral leishmaniasis (CVL) prevention through the characterization of Leishmania antigens as vaccine candidates. Despite these efforts, there is still no efficient vaccine for CVL control. Methods: In the present study, we performed a pre-clinical vaccine trial using BALB/c mice to compare the effects of the multicomponent LBSap vaccine with those of Leish-Tec® and Leishmune®. Blood was collected to determine the frequency of peripheral blood cells and to evaluate hematologic and immunophenotypic parameters. Liver and spleen samples were collected for parasitological quantification, and spleen samples were used to access the cytokine profile. Results: When measuring total IgG and IgG1 anti-Leishmania levels after the third vaccination and L. infantum challenge, it was evident that all vaccines were able to induce humoral immune response. Regarding the innate immune response, increased levels of NK CD3-CD49+ cells were the hallmark of all vaccinated groups, whereas only the Leish-Tec® group displayed a high frequency of CD14+ monocytes after L. infantum challenge. Moreover, CD3+CD4+ T cells were the main circulating lymphocytes induced after L. infantum challenge with all evaluated vaccines. Importantly, after L. infantum challenge, splenocytes from the Leishmune® vaccine produced high levels of IL-2, whereas a prominent type 1 immune response was the hallmark of the LBSap vaccine, which presented high levels of IL-2, IL-6, TNF-α, and IFN-γ. The efficacy analysis using real-time polymerase chain reaction demonstrated a reduction in the parasitism in the spleen (Leishmune®: 64 %; LBSap: 42 %; and Leish-Tec®: 36 %) and liver (Leishmune®: 71 %; LBSap: 62 %; and Leish-Tec®: 48 %). Conclusions: The dataset led to the conclusion that the LBSap vaccination was able to induce immune and efficacy profiles comparable with those of commercial vaccines, thus demonstrating its potential as a promising vaccine candidate for visceral leishmaniasis control.
ISSN: 1756-3305
metadata.dc.rights.license: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Fonte: o própio artigo.
Appears in Collections:DEACL - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_MulticomponentLBSapVaccine.pdf1,52 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.